| Trial | CV6-168 combination Phase I/IIa trial |
|---|---|
| Cancer Type | Miscellaneous and Non-specific |
| Hospital(s) | Belfast City Hospital |
| Information | CV6-168 – A First in Human Modular, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of the specific dUTPase inhibitor CV6-168 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies |
| Trial | DETERMINE |
|---|---|
| Cancer Type | Miscellaneous and Non-specific |
| Hospital(s) | Belfast City Hospital |
| Information | Determining Extended Therapeutic indications for Existing drugs in Rare Molecularly-defined Indications using a National Evaluation platform trial |
 |
Click Here to view Cancer Research UK trial summary |
| Trial | TAK-676-1002 |
|---|---|
| Cancer Type | Miscellaneous and Non-specific |
| Hospital(s) | Belfast City Hospital |
| Information | An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors. |
| Trial | TARGET-National |
|---|---|
| Cancer Type | Miscellaneous and Non-specific |
| Hospital(s) | Belfast City Hospital |
| Information | Tumour Characterization to Guide Experiential Targeted Therapy – National |
| Trial | VIVO Biobank |
|---|---|
| Cancer Type | Children’s Cancer, Miscellaneous, and Non-specific |
| Hospital(s) | Royal Belfast Hospital for Sick Children |
| Information | A UK Biobank dedicated to cancer research in children and young people |
|
Click Here to view Cancer Research UK trial summary |